ekincare raises investment from MSD IDEA Studio Asia Pacific

ekincare has raised a total funding of $22M since 2015 till date

Nissan Chemical extends supply agreement with MSD Animal Health for Fluralaner

Fluralaner invented by Nissan Chemical is the active pharmaceutical ingredient of BRAVECTO and EXZOLT,

MSD enters into license agreement with Hansoh Pharma for investigational Oral GLP-1 receptor agonist

MSD and MPP sign licensing agreement to make molnupiravir affordable

In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.

MSD India launches 9-valent Human Papillomavirus (HPV) vaccine, GARDASIL 9

India’s first gender-neutral HPV vaccine to help reduce HPV -related disease burden in Indian girls, women and boys

Merck breaks ground on new $1 billion Biologics Center of Excellence in Delaware, US

Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA

Merck seeks FDA approval for subcutaneous pembrolizumab

Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy

European Commission approves Merck’s Capvaxive for prevention of invasive pneumococcal disease

EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults

Merck inks $200 million deal for Hengrui's midstage heart disease drug

Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region

Merck’s Welireg receives European approval for two indications

WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union